Buckingham Strategic Partners Regeneron Pharmaceuticals, Inc. Transaction History
Buckingham Strategic Partners
- $4.37 Billion
- Q3 2024
A detailed history of Buckingham Strategic Partners transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Buckingham Strategic Partners holds 371 shares of REGN stock, worth $250,718. This represents 0.01% of its overall portfolio holdings.
Number of Shares
371
Previous 368
0.82%
Holding current value
$250,718
Previous $386,000
1.04%
% of portfolio
0.01%
Previous 0.01%
Shares
6 transactions
Others Institutions Holding REGN
# of Institutions
1,497Shares Held
82.8MCall Options Held
1.22MPut Options Held
1.51M-
Vanguard Group Inc Valley Forge, PA9.32MShares$6.3 Billion0.18% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$5.71 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY7.49MShares$5.06 Billion0.64% of portfolio
-
State Street Corp Boston, MA4.9MShares$3.31 Billion0.21% of portfolio
-
Capital World Investors Los Angeles, CA4.3MShares$2.9 Billion0.72% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $72.4B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...